Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaffer Ajani

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Journal of the National Comprehensive Cancer Network : JNCCN|February 3, 2006
Neuroendocrine tumorsOrlo H Clark, Jaffer Ajani, Al B Benson, et al.
Nature Medicine|March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trialKohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Pan-cancer subclonal mutation analysis of 7,827 tumors predicts clinical outcomeYujie Jiang, Matthew D Montierth, Kaixian Yu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2006
Esophageal Cancer Clinical Practice GuidelinesJaffer Ajani, Tanios Bekaii-Saab, Thomas A D'Amico, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2006
Gastric Cancer Clinical Practice GuidelinesJaffer Ajani, Tanios Bekaii-Saab, Thomas A D'Amico, et al.
Nature Communications|August 24, 2024
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomicsJiahui Jiang, Yunhe Liu, Jiangjiang Qin, et al.
Nature Communications|September 24, 2021
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapyGuangchun Han, Guoliang Yang, Dapeng Hao, et al.
The New England Journal of Medicine|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal CancerKohei Shitara, Elena Elimova, Tianshu Liu, et al.
Gastroenterology|August 23, 2015
Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association SymposiumPrateek Sharma, David A Katzka, Neil Gupta, et al.
Cancer Cell|March 24, 2012
The crosstalk of mTOR/S6K1 and Hedgehog pathwaysYan Wang, Qingqing Ding, Chia-Jui Yen, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Journal of the National Comprehensive Cancer Network : JNCCN|February 3, 2006
Neuroendocrine tumorsOrlo H Clark, Jaffer Ajani, Al B Benson, et al.
Nature Medicine|March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trialKohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Pan-cancer subclonal mutation analysis of 7,827 tumors predicts clinical outcomeYujie Jiang, Matthew D Montierth, Kaixian Yu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2006
Esophageal Cancer Clinical Practice GuidelinesJaffer Ajani, Tanios Bekaii-Saab, Thomas A D'Amico, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2006
Gastric Cancer Clinical Practice GuidelinesJaffer Ajani, Tanios Bekaii-Saab, Thomas A D'Amico, et al.
Nature Communications|August 24, 2024
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomicsJiahui Jiang, Yunhe Liu, Jiangjiang Qin, et al.
Nature Communications|September 24, 2021
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapyGuangchun Han, Guoliang Yang, Dapeng Hao, et al.
The New England Journal of Medicine|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal CancerKohei Shitara, Elena Elimova, Tianshu Liu, et al.
Gastroenterology|August 23, 2015
Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association SymposiumPrateek Sharma, David A Katzka, Neil Gupta, et al.
Cancer Cell|March 24, 2012
The crosstalk of mTOR/S6K1 and Hedgehog pathwaysYan Wang, Qingqing Ding, Chia-Jui Yen, et al.
Pageof 11